

organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the name and principal place of business of the standards development organization is: World Wide Web Consortium, Inc., Wakefield, MA. W3C was formed as a Delaware non-stock member corporation, organized exclusively for exempt purposes within the meaning of section 501(c)(3) of the Internal Revenue Code of 1986, as amended (or the corresponding provision of any future United States Internal Revenue Law). The nature and scope of W3C's standards development activities are: In furtherance of such purposes, W3C is organized and will be operated primarily to continue the work of the unincorporated World Wide Web Consortium, with the charitable purpose of inclusively developing interoperability standards for the infrastructure of the World Wide Web ("Web"), so that all people may safely and productively use the Web to participate in society and improve their lives. W3C seeks to achieve its purpose by creating open, consensus-based Web standards and guidelines to ensure that the Web remains open, accessible, and interoperable for everyone around the globe, through processes intended to promote fairness, transparency, and accountability, and enable progress and greater responsiveness to change. Without limiting the foregoing, W3C, through its member-driven approach, will work to (a) foster a consistent architecture accommodating the rapid pace of progress in Web standards for websites, browsers, data-sharing applications, and devices to experience all that the Web has to offer; (b) provide a neutral forum where organizations around the world come together to create the technologies to most fully realize the potential of the Web; (c) ensure that all foundational Web technologies meet the needs of civil society, in areas such as accessibility, internationalization, security, and privacy; (d) provide standards that undergird the infrastructure for modern businesses leveraging the Web in areas such as entertainment, communications, digital publishing, and financial services; (e) promote advances of important associated social and economic value; and (f) promote the emergence of current and future transformative phenomena, such as

social media, e-commerce, video on the web, and video conferencing.

Suzanne Morris,

Deputy Director, Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023-10207 Filed 5-11-23; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—ODVA, Inc.

Notice is hereby given that, on March 20, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), ODVA, Inc. ("ODVA") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Inexbot Technology Co. Ltd., Nanjing, PEOPLE'S REPUBLIC OF CHINA, has been added as a party to this venture.

Also, Asyryl SA, Fribourg, SWITZERLAND; and Telsonic AG, Bronschhofen, SWITZERLAND, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and ODVA intends to file additional written notifications disclosing all changes in membership.

On June 21, 1995, ODVA filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on February 15, 1996 (61 FR 6039).

The last notification was filed with the Department on January 5, 2023. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on January 25, 2023 (88 FR 4851).

Suzanne Morris,

Deputy Director, Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023-10209 Filed 5-11-23; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Asim A. Hameedi, M.D.; Stay of Decision and Transmittal Order

On April 4, 2023, the Agency issued a Decision and Order revoking, effective May 11, 2023, Certificate of Registration No. BH6407919 issued to Asim A. Hameedi, M.D.¹ *Asim A. Hameedi, M.D.*, 88 FR 21,715 (April 11, 2023). By letter dated May 1, 2023 (letter), addressed to the Drug Enforcement Administration Administrator, Dr. Hameedi requested that the April 4, 2023 Order be vacated² because, among other reasons, he was never served with the underlying Order to Show Cause. Letter, at 1. Given the content of the letter and its attachments, I hereby stay the revocation of Certificate of Registration No. BH6407919 issued to Asim A. Hameedi, M.D., pending further proceedings. *Asim A. Hameedi, M.D.*, 88 FR 21,715 (April 11, 2023).

This matter is transmitted to the Office of Administrative Law Judges to conduct any and all appropriate proceedings (for example, to determine the sufficiency of notice and/or whether good cause exists to justify any delay).

It is so ordered.

Signing Authority

This document of the Drug Enforcement Administration was signed on May 9, 2023, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2023-10212 Filed 5-11-23; 8:45 am]

BILLING CODE 4410-09-P

¹ The Order also denied any pending application to renew or modify this registration and denied any other pending application by Dr. Hameedi for registration in New York.

² Dr. Hameedi also seeks to "excuse his default" citing to 21 CFR 1301.43(c)(1) and (f)(3). Letter, at 1. The default procedures Dr. Hameedi references did not become effective until December 14, 2022, and do not apply to his Order to Show Cause. 87 FR 73,246 (Nov. 29, 2022).